Mucin Fusion Polypeptide Vaccines, Compositions And Methods Of Use Thereof

Abstract

The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins.

1 . A purified composition comprising:
 a dimerized fusion polypeptide comprising a first polypeptide linked to a second polypeptide, wherein the first polypeptide is a mucin polypeptide and is glycosylated by a α1,3 galactosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide covalently linked to a third polypeptide, wherein the third polypeptide is a tumor associated antigen.   
     
     
         2 . The composition of  claim 1 , wherein the first polypeptide comprises at least a region of a P-selectin glycoprotein ligand-1. 
     
     
         3 . The composition of  claim 1 , wherein the first polypeptide comprises amino acids 19-319 of human P-selectin glycoprotein ligand-1 when numbered in accordance with wild type human P-selectin glycoprotein ligand-1. 
     
     
         4 . The composition of  claim 1 , wherein the second polypeptide comprises a region of a heavy chain immunoglobulin polypeptide. 
     
     
         5 . The composition of  claim 1 , wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain. 
     
     
         6 . The composition of  claim 1 , further comprising an adjuvant compound. 
     
     
         7 . A method of immunization in a subject at risk of developing cancer, the method comprising administering to the subject an effective dose of the composition of  claim 1 .